Top Ten most popular articles on Pharmafile.com this week
pharmafile | August 17, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AbbVie, CMO, Litigation, OxyContin, Purdue Pharma, approvals, top 10
This week’s pharmaceutical headlines were dominated by legal spats as the state of New York sued OxyContin drug maker Purdue Pharma and a Chicago judge overturned a $140 million verdict against AbbVie while Indian biotech owner Nitin Sandesara was detained in Dubai.
However the biggest story of the week covered Allergan’s appointment of Pfizer CMO Charles Hugh-Jones as their new Senior Vice President and Chief Medical Officer. Meanwhile Gilead’s CMO announced his departure, as the company appointed two new executives.
For all the latest pharmaceutical news and updates, check out this week’s ten most popular articles on Pharmafile.com now!
10. NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay
UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available treatment for the condition.
9. Indian biotech owner detained in Dubai over £550m fraud allegations
Indian businessman Nitin Sandesara, the owner of the Gujarat-based pharmaceutical company Sterling Biotech has been detained in Dubai in relation to INR 50 billion (£550 million) fraud allegations.
8. Astellas acquires gene therapy group Quethera in £85 million deal
The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million.
7. New York sues Purdue Pharma over opioid crisis
New York State have sued OxyContin drug maker Purdue Pharma over allegations surrounding widespread fraud and deception in the marketing of opioids.
6. “Triple pill” blood pressure combo proves more effective, safe than standard care
A “triple pill” combining three established and effective drugs at low dosage levels could prove much more effective in treating high blood pressure than any of its constituent elements alone, according to research conducted by the George Institute for Global Health.
5. Gilead CMO announces departure alongside two new exec appointments
Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the company in order to “pursue another opportunity”.
4. ABPI Chief warns of Brexit impact on EU
The head of the Association of the British Pharmaceutical Industry (ABPI) has warned that European governments have failed to recognise the impact a no-deal Brexit would have on medical supply chains between Europe and the UK.
3. NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), expanding its use to cover treatment-naïve patients with chronic lymphoblastic forms of the condition (CLL).
2. Chicago Judge overturns $140 million AbbVie AndroGel verdict
A US Judge has overturned a $140.1 million verdict against the New York-listed AbbVie Inc.
1. Pfizer CMO Charles Hugh-Jones set to join Allergan in return to New Jersey
Allergan has appointed Pfizer CMO Charles Hugh-Jones as their new Senior Vice President and Chief Medical Officer, as the board certified physician makes a return to New Jersey.
Related Content
AbbVie invests €150m in new R&D facility in Germany
AbbVie has announced that it is investing approximately €150m in its second largest research and …
Medincell and AbbVie enter agreement for development of next-generation injectables
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …
AbbVie to acquire Landos Biopharma for approximately $137.5m
AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under …
